Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / ADMP - Adamis' COVID treatment gets OK to proceed in phase 2/3 from DSMB

ADMP - Adamis' COVID treatment gets OK to proceed in phase 2/3 from DSMB

Adamis Pharmaceuticals Corporation
A Data Safety Monitoring Board has determined that Adamis Pharmaceuticals' (NASDAQ:ADMP) phase 2/3 trial for its COVID-19 candidate tempol can continue without any changes. Shares are up 5% in premarket trading. The decision was reached following an evaluation of an interim analysis of efficacy and safety data. Adamis (ADMP) said that tempol can also potentially be used for influenza and respiratory syncytial virus. The company recently announced that its board chairman will retire in April.

For further details see:

Adamis' COVID treatment gets OK to proceed in phase 2/3 from DSMB
Stock Information
Company Name: Adamis Pharmaceuticals Corporation
Stock Symbol: ADMP
Market: NASDAQ
Website: adamispharmaceuticals.com
Menu
ADMP ADMP Quote ADMP Short ADMP News ADMP Articles ADMP Message Board
Get ADMP Alerts

News, Short Squeeze, Breakout and More Instantly...